Bausch Health Companies Inc. says refinancing extended approximately $6,870 million of debt maturities from 2025 through 2028 to 2030 through 2032 while it continues evaluating separation of approximately 87%-owned Bausch + Lomb.
BHC · Bausch Health Companies Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $8.56
- Open
- $8.71
- Day range
- $8.55–8.84
- 52-week closing range
- $4.43–8.91
- Average volume, 30 days
- 4.1M
- Short interest
- 7.4M · 2.0% of shares · 1.2 days
- Short volume, last session
- 29%
- Last earnings
- Oct 28, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Bausch Health raised its full-year 2026 guidance for the second time this year, with revenue now expected between $5,525,000,000 and $5,625,000,000 and adjusted EBITDA between $3,225,000,000 and $3,275,000,000. Revenues reached $2,941,000,000, a 10% increase on reported basis. The company also reduced its net debt by $521 million during the quarter.
Bausch Health reported third-quarter 2026 revenue of $2.94 billion, up 10% from $2.68 billion a year earlier, and GAAP net income attributable to Bausch Health of $436 million. Adjusted earnings per diluted share rose to $1.77 from $1.16, and full-year 2026 revenue and Adjusted EBITDA guidance was raised. The Board authorized a $50 million share repurchase program.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 28, 2026TL;DR. Third-quarter revenue, adjusted EBITDA and operating cash flow grew strongly, management raised full-year guidance for all three metrics, and net debt declined by $521 million during the quarter. Offsetting these gains, Xifaxan pricing and inventory headwinds are expected to pressure Q4 and 2027, Solta organic revenue declined 4%, and tariffs remain an uncertain risk.
- + Third-quarter consolidated revenue rose 10% to $2,941,000,000, adjusted EBITDA rose 32% to $1,305,000,000, and adjusted cash flow from operations rose 54% to $782 million.
- + Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations for the second consecutive quarter.
- + The updated Bausch Health guidance excluding Bausch + Lomb calls for revenue of $5.525 billion to $5.625 billion, adjusted EBITDA of $3.225 billion to $3.275 billion, and adjusted cash flow from operations of $1.600 billion to $1.675 billion.
- + Cash generation reduced net debt by $521 million during the quarter and by more than a billion dollars since the beginning of the year, while the company ended with $2 billion of cash on hand.
- + Salix revenue increased 16% to $831 million, led by 16% Xifaxan growth from favorable pricing and solid demand.
- + International revenue grew 4% organically, with EMEA delivering a 15th consecutive quarter of organic growth and Canada returning to growth.
- − The anticipated Xifaxan Medicare price change is expected to reduce Q4 revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points.
- − Xifaxan inventory normalization could further reduce Q4 revenue growth by at least 300 basis points and adjusted EBITDA growth by 500 basis points.
- − The net impact of Xifaxan pricing and rebate changes is expected to reduce 2027 revenue by approximately $400 million to $500 million year over year.
- − Solta Medical organic revenue declined 4% in the third quarter despite reported growth of 18%.
- − The company incurred a $1,426 million goodwill impairment during the first nine months and reported a nine-month net loss attributable to Bausch Health of $729 million.
- − Tariff developments create uncertainty, and the company said there can be no assurance that the impacts will not be adverse.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic Revenue (Non-GAAP) - Bausch + Lomb non-GAAP | $1.38B | the three months ended June 30, 2026 filing | — |
| Organic Revenue (Non-GAAP) - Diversified non-GAAP | $219M | the three months ended June 30, 2026 filing | — |
| Organic Revenue (Non-GAAP) - International non-GAAP | $293M | the three months ended June 30, 2026 filing | — |
| Organic Revenue (Non-GAAP) - Salix non-GAAP | $758M | the three months ended June 30, 2026 filing | — |
| Organic Revenue (Non-GAAP) - Solta Medical non-GAAP | $143M | the three months ended June 30, 2026 filing | — |
| Adjusted Cash Flows from Operations non-GAAP | $471M | the second quarter of 2026 | — |
| Adjusted cash flows from operations (non-GAAP) non-GAAP | $1.01B | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) non-GAAP | $1.97B | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) non-GAAP | $1.91B | Six Months Ended June 30, 2026 | — |
| Consolidated adjusted earnings per share attributable to Bausch Health (non-GAAP) non-GAAP | $1.26 | the second quarter of 2026 | — |
| Consolidated adjusted net income attributable to Bausch Health (non-GAAP) non-GAAP | $476M | the second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) attributable to Bausch Health Companies Inc. 258M
+225M Amortization of intangible assets
+0M Goodwill impairments
+9M Asset impairments
+14M Restructuring, integration and transformation costs
+6M Acquisition-related costs and adjustments (excluding amortization of intangible assets)
+0M (Gain) loss on extinguishment of debt and write down of financing fees
+1M Separation costs and separation-related costs
+0M Gain on sale of assets, net
+6M Litigation and other matters, net of insurance recoveries and restitutions
+6M Other
-35M Tax effect of non-GAAP adjustments
-14M Noncontrolling interest portion of the non-GAAP adjustments
= Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP) 476M
|
|||
| Organic Revenue (Non-GAAP) non-GAAP | $5.21B | Six Months Ended June 30, 2026 | — |
| Organic Revenue Growth (Salix segment) non-GAAP | 21% | the second quarter of 2026 | — |
| Organic Revenue Growth (Total Bausch Health) non-GAAP | 11% | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHC
this stock
Bausch Health Companies Inc.
|
$3.20B | +23.2% | -9.8% | — | 2.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.89B | +5.3% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 18
Bausch Health Companies Inc. says refinancing extended approximately $6,870 million of debt maturities from 2025 through 2028 to 2030 through 2032 while it continues evaluating separation of approximately 87%-owned Bausch + Lomb.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHC | +3.8% | +31.9% | +61.2% | +4.4% | +23.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +9.2% | +38.2% | +66.8% | +9.7% | +18.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.